Welcome to our dedicated page for Jasper Therapeutics news (Ticker: JSPR), a resource for investors and traders seeking the latest updates and insights on Jasper Therapeutics stock.
Jasper Therapeutics develops briquilimab, a clinical-stage antibody therapy targeting KIT (CD117) for mast cell driven diseases including chronic spontaneous urticaria, chronic inducible urticaria and asthma. Company news centers on briquilimab clinical data from BEACON, open-label extension and ETESIAN studies, financial results and corporate updates, investor conference participation, financing activity and governance changes tied to its development strategy.
On February 2, 2023, Jasper Therapeutics (Nasdaq: JSPR) granted Ronald Martell, its President and CEO, a True-Up Option to purchase 1,093,831 shares of common stock. This option was granted after Jasper closed a public offering raising approximately $103.5 million on January 27, 2023. The True-Up Option has an exercise price of $1.78 per share and will vest over four years. Jasper, focused on novel antibody therapies targeting c-Kit for conditions like chronic spontaneous urticaria and myelodysplastic syndromes, aims to advance briquilimab as a therapeutic agent. The grant complies with Nasdaq Listing Rule 5635(c)(4), reflecting Jasper's commitment to employee incentive plans.
Jasper Therapeutics will host a corporate update conference call on January 31, 2023, from 8:30 am – 9:30 am Eastern Time. The call will be led by the management team and can be accessed by phone or through a live webcast available on their investor relations website. Jasper is focused on developing briquilimab, a monoclonal antibody targeting c-Kit (CD117) for conditions such as chronic spontaneous urticaria and myelodysplastic syndromes (MDS). To date, the drug has shown safety and efficacy in over 130 participants. A replay of the webcast will be available for 90 days.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has successfully completed a public offering of 69 million shares at $1.50 per share, raising approximately $103.5 million. The offering price includes an additional 9 million shares purchased by underwriters. Proceeds will support the development of briquilimab, a monoclonal antibody targeting c-Kit, aimed at treating chronic urticaria and myelodysplastic syndromes (MDS), along with potential use in stem cell transplant conditioning. Credit Suisse and William Blair served as book-running managers for the offering, which was run under an effective registration statement with the SEC.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) has priced its underwritten public offering of 60,000,000 shares of common stock at $1.50 per share, raising approximately $90 million. The net proceeds are intended for general corporate purposes, including capital expenditures and working capital. The offering is set to close on January 27, 2023, subject to customary closing conditions. Additionally, underwriters have a 30-day option to purchase up to 9,000,000 shares at the public offering price. The offering is conducted under an effective shelf registration statement with the SEC.
Jasper Therapeutics (Nasdaq: JSPR) announced plans for an underwritten public offering of common stock, subject to market conditions. The company intends to give underwriters a 30-day option to purchase an additional 15% of the shares. All shares will be sold by Jasper, with the offering facilitated by Credit Suisse Securities and William Blair & Company as active managers. The shares will be offered under an effective shelf registration. Proceeds from the offering may support the company's development of briquilimab, a monoclonal antibody targeting c-Kit for various diseases and stem cell transplants.
Jasper Therapeutics (Nasdaq: JSPR) announced positive data regarding its investigational monoclonal antibody, briquilimab (formerly JSP191), at the 2023 ASTCT Meetings. Three abstracts highlighted the safety and efficacy of briquilimab combined with low-dose radiation for treating older adults (median age 70) with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Key findings include durable remission in 8 of 12 AML patients after one year, lower than expected rates of graft-versus-host disease (GVHD) in 29 patients, and potential cost savings from outpatient procedures. These data support briquilimab's role in improving stem cell transplant safety and efficacy.
Jasper Therapeutics, Inc. (Nasdaq: JSPR) is prioritizing its lead product briquilimab for chronic diseases and stem cell transplant in its portfolio. The new focus includes a clinical study on chronic urticaria and continued work on lower-risk MDS, SCID, and sickle cell disease. The company aims to rapidly initiate trials based on strong preclinical data supporting briquilimab's efficacy. Jasper plans to present new data at the 2023 Tandem Meetings, reinforcing its therapeutic potential in several indications. The company emphasizes a clear path forward for investor value and patient benefit.
Jasper Therapeutics (NASDAQ: JSPR) has received orphan drug designation from the European Medicines Agency for briquilimab, a monoclonal antibody targeting CD117, aimed at conditioning treatments before hematopoietic cell transplantation (HCT). This follows prior orphan drug status granted by the FDA in both HCT and for severe combined immunodeficiency (SCID). CEO Ronald Martell emphasized the importance of briquilimab in reducing toxicities associated with traditional conditioning. Clinical trials show promising results in SCID and acute myeloid leukemia patients, with no significant adverse events reported.
Jasper Therapeutics, Inc. (NASDAQ: JSPR) announced positive results from a Phase 1/2 clinical trial involving briquilimab, aimed at treating sickle cell disease (SCD). All three participants achieved neutrophil engraftment within 12-16 days, with the first participant showing a significant increase in total hemoglobin from 8-9 g/dL to 13.3 g/dL at five months. The trial seeks to enhance donor cell chimerism while minimizing toxicity from conditioning regimens. The study is currently enrolling patients at the NHLBI.
Jasper Therapeutics, Inc. (JSPR) reported strong clinical data for JSP191 at the IEWP Annual Meeting, achieving 100% donor chimerism in two Fanconi Anemia patients. The FDA granted Fast Track designation for JSP191 in treating Severe Combined Immunodeficiency (SCID), highlighting a significant medical need. Upcoming studies include JSP191 for lower-risk myelodysplastic syndromes (MDS) and a registrational study in acute myeloid leukemia (AML) set for early 2023. Financially, the company reported a net loss of $11.9 million for Q3 2022, an increase from $3.4 million the previous year.